Last edition
News about "Astellas Pharma"
The European Commission has approved Padcev in combination with Keytruda as the first perioperative treatment for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer in Europe.
Astellas Pharma | 25/06/2026 | By News Bureau
FDA Grants Priority Review to Astellas and Pfizer's Bladder Cancer Combination Therapy
Astellas and Pfizer’s Padcev-Keytruda combination moves closer to expanded approval, offering a potential new treatment option to reduce recurrence and improve survival in bladder cancer patients.
Astellas Pharma | 21/04/2026 | By News Bureau | 117
US FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC).
Astellas Pharma | 24/11/2025 | By Dineshwori | 174
Astellas and Japanese Foundation for Cancer Research to Accelerate Clinical Oncology Research
Through this collaboration, Astellas is committed to strengthening translational science and clinical research in order to deliver innovative new medicines.
Astellas Pharma | 04/04/2025 | By Aishwarya | 414
Astellas and YASKAWA to Establish Joint Venture Focused on Cell Therapy Manufacturing
The planned joint venture will leverage Astellas' expertise in R&D and manufacturing for cell therapy and the dual arm robot ‘Maholo’, developed by YASKAWA's subsidiary, Robotic Biology Institute.
Astellas Pharma | 06/03/2025 | By Aishwarya | 321
Axcelead DDP Signs Drug Discovery Service Deal with Astellas for Targeted Protein Degraders
Under the agreement, Axcelead DDP will support Astellas’ targeted protein degrader discovery utilizing DegLeadTM Platform and contribute to the generation of breakthrough new drug candidate compounds.
Astellas Pharma | 27/12/2024 | By Aishwarya | 341
Astellas Pharma and YASKAWA Sign MOU to Explore Innovative Cell Therapy Ecosystem
Astellas will contribute cell manufacturing technology, clinical development, and regulatory insights related to cell therapy, while YASKAWA will provide and develop robotics and factory automation technologies.
Astellas Pharma | 21/05/2024 | By Abha | 675
Astellas Signs License Deal with Poseida to Develop Novel Allogeneic Cell Therapies
Astellas Pharma Inc. has announced that Xyphos Biosciences, Inc., a wholly owned subsidiary of Astellas and Poseida have signed a research collaboration and license agreement to develop novel convertibleCAR programs by combining the innovative cell therapy platforms from each of the companies.
Astellas Pharma | 03/05/2024 | By Aishwarya | 422
Invenra Signs Research Deal with Astellas Pharma to Boost Bispecific Therapeutic Research
Invenra Inc. has forged a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.
Astellas Pharma | 10/04/2024 | By Aishwarya | 717
Astellas Pharma to Transfer Manufacturing Plant, Business to Delpharm
Astellas Pharma announced that Astellas B.V., Astellas Pharma Europe B.V., and Astellas’ subsidiaries in the Netherlands have decided to sell and transfer the manufacturing plant located in Meppel to Delpharm Industries.
Astellas Pharma | 30/05/2023 | By Sudeep Soparkar | 761
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy